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ARTICLE
Tuning microtubule dynamics to enhance cancer
therapy by modulating FER-mediated CRMP2
phosphorylation
Yiyan Zheng1,2, Ritika Sethi3, Lingegowda S. Mangala4,5, Charlotte Taylor1,2, Juliet Goldsmith1,2, Ming Wang1,2,
Kenta Masuda1,2, Mohammad Karaminejadranjbar1,2, David Mannion1,2, Fabrizio Miranda1,2,
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Sunanda Dhar14, David Ferguson 15, Robert C. Bast Jr.9, Anil K. Sood4,5, Frank von Delft 3,16,17
& Ahmed Ashour Ahmed1,2
Though used widely in cancer therapy, paclitaxel only elicits a response in a fraction of
patients. A strong determinant of paclitaxel tumor response is the state of microtubule
dynamic instability. However, whether the manipulation of this physiological process can be
controlled to enhance paclitaxel response has not been tested. Here, we show a previously
unrecognized role of the microtubule-associated protein CRMP2 in inducing microtubule
bundling through its carboxy terminus. This activity is signiﬁcantly decreased when the FER
tyrosine kinase phosphorylates CRMP2 at Y479 and Y499. The crystal structures of wild-
type CRMP2 and CRMP2-Y479E reveal how mimicking phosphorylation prevents tetra-
merization of CRMP2. Depletion of FER or reducing its catalytic activity using sub-therapeutic
doses of inhibitors increases paclitaxel-induced microtubule stability and cytotoxicity in
ovarian cancer cells and in vivo. This work provides a rationale for inhibiting FER-mediated
CRMP2 phosphorylation to enhance paclitaxel on-target activity for cancer therapy.
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Paclitaxel increases microtubule polymerization and stability,induces mitotic arrest, promotes cancer cell death, andimproves patient survival1,2. However, paclitaxel only elicits
a response in a fraction of patients3. Poor pharmacokinetics
represents a major obstacle for appropriate drug delivery.
Therefore, it is likely that paclitaxel interacts with microtubules in
cancer cells at sub-stoichiometric concentrations4. Alternative
formulations have already shown promise in enhancing paclitaxel
pharmacokinetics and, thereby, its efﬁcacy, highlighting the need
for overcoming sub-optimal on-target activity5.
Previous work has shown that microtubule dynamics of cancer
cells have a profound effect on the magnitude of paclitaxel
response. For example, mutations in the non-binding sites for
paclitaxel in α-tubulin or β-tubulin result in an increase in
microtubule dynamic instability and signiﬁcant paclitaxel resis-
tance6,7. Similarly, overexpression of βIII-tubulin which is asso-
ciated with an increase in dynamic instability has been shown to
correlate with clinical resistance to paclitaxel8. We and others have
previously shown that the state of microtubule stability in cancer
cells prior to treatment is an important determinant of the mag-
nitude of paclitaxel-induced microtubule stabilization9–12. How-
ever, whether microtubule dynamics manipulation can be exploited
for enhancing paclitaxel cytotoxicity has remained untested.
Collapsin response mediator protein 2 (CRMP2) is an intra-
cellular phosphoprotein that plays an important role in regulating
cytoskeletal dynamics. It forms a tetramer that interacts with
tubulin13 or pre-formed microtubules14 to modulate important
microtubule functions such as neuronal axonal growth and axon-
dendrite fate determination15. It is thought to inﬂuence micro-
tubule assembly via its interactions with αβ-tubulin hetero-
dimers13. Several key kinases are reported to phosphorylate
CRMP2 at the carboxy terminus, thereby inhibiting its binding
activity to tubulin. For example, serine/threonine phosphoryla-
tion of CRMP2 via glycogen synthase kinase 3β (GSK3β) or
cyclin-dependent kinase 5 (CDK5) interferes with the ability of
CRMP2 to bind to tubulin16–19. However, whether or not
CRMP2 can modulate microtubule bundling and stability and
whether such functions are regulated by phosphorylation has not
been previously established.
Here, we report that FER phosphorylates CRMP2 at Y479 and
Y499, resulting in a signiﬁcant structural change of CRMP2 that
reduces its ability to induce microtubule bundling. Inactivation of
FER increases microtubule stability in ovarian cancer cells,
potentiating the cytotoxicity of paclitaxel. Our data identify FER
tyrosine kinase as a plausible target for therapy that acts in
synergy with one of the most commonly used chemotherapeutic
drugs in the treatment of ovarian cancer.
Results
FER phosphorylates CRMP2 at Y479 and Y499. We set out to
identify a microtubule-associated protein whose function: (1) is
modulated by an oncogene kinase that could be targeted ther-
apeutically and (2) directly controls microtubule bundling and
stability. FER kinase has been reported to promote ovarian cancer
metastasis20. Its expression level has been previously correlated
with the level of microtubule stability12. In addition, previous
reports found that FES, the only other family member of FER, is
able to phosphorylate CRMP2 at Y3221. CRMP2 has been
reported to be a known modulator of microtubule assembly13.
We, therefore, tested whether CRMP2 can modulate microtubule
bundling and stability and whether this function can be regulated
by FER. In vitro kinase assays using a catalytically active glu-
tathione S-transferase (GST)-tagged truncation of FER (residues
541–822) and recombinant CRMP2 (residues 13–516) conﬁrmed
that FER phosphorylates CRMP2 (Supplementary Fig. 1a).
Importantly, using puriﬁed recombinant CRMP2 and tubulin that
was puriﬁed from pig brains (Supplementary Fig. 1b), we found
that FER phosphorylation of CRMP2 signiﬁcantly reduced its
microtubule polymerizing activity as evidenced by light scatter
assays (Supplementary Fig. 1c). Using total internal reﬂection
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Fig. 1 FER phosphorylation of CRMP2 impairs its microtubule bundling
activity. a Paclitaxel-stabilized rhodamine-labeled microtubules were
incubated in the absence or presence of CRMP2 or pCRMP2
(phosphorylated by FER kinase) at room temperature for 40min before
ﬂuorescence microscopy was performed and images were obtained. Bar
plots represent the mean + s.e.m. of microtubule width in µm from at least
150 individual microtubules per condition tested. Data presented are typical
of at least three independent replicates. Scale bar is 10 µm. b Electron
microscopy images of microtubules in the absence or presence of
recombinant 6His-CRMP2. The dashed rectangles in the left panel are the
areas zoomed in on the right panel. Scale bar is 100 nm. c Recombinant
6His-CRMP2 (residues 13–516) was puriﬁed and incubated with paclitaxel-
stabilized microtubules for 30min at room temperature. Subsequently, the
samples were ultracentrifuged at 200,000×g for 30min before analysis
using SDS-PAGE and coomassie staining. S: supernatant, P: pellet. d
Paclitaxel-stabilized rhodamine-labeled microtubules were incubated in the
absence or presence of CRMP2 at room temperature for 40min. CRMP2
localization was revealed by anti-CRMP2 antibody. Scale bar is 10 µm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02811-7
2 NATURE COMMUNICATIONS |  (2018) 9:476 |DOI: 10.1038/s41467-017-02811-7 |www.nature.com/naturecommunications
ﬂuorescence microscopy (TIRFM) to monitor the elongation of
individual microtubules, we found that pCRMP2 (phospho-
CRMP2) had a signiﬁcant impairment in its ability to induce
microtubule elongation (Supplementary Fig. 1d and Supple-
mentary movie 1–3). In addition, pre-formed, paclitaxel-treated,
rhodamine-labeled single microtubules were incubated with
recombinant CRMP2 proteins and observed using ﬂuorescence
microscopy. This revealed that CRMP2 induced a signiﬁcant
increase in the width of microtubules (Fig. 1a), an observation
that was akin to microtubule bundling induced by paclitaxel1.
Electron microscopy conﬁrmed that CRMP2 induced signiﬁcant
re-organization of microtubules in sheet structures composed
of individual parallel microtubules with frequent overlap between
the sheets (Fig. 1b and Supplementary Fig. 1e). In addition,
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in vitro co-sedimentation assays showed that most of
CRMP2 (residues 13–516) co-sedimented with microtubules in
the pellet fraction (P). In contrast, most of CRMP2 remained
in the supernatant (S) in the absence of microtubules (Fig. 1c)
supporting the notion that CRMP2 was able to directly bind to
microtubules. Furthermore, CRMP2 co-localized with paclitaxel-
stabilized, rhodamine-labeled microtubules as shown by ﬂuores-
cence microscopy (Fig. 1d). Thus, we provide strong evidence
that CRMP2 directly induces microtubule bundling. Since we
used paclitaxel-stabilized microtubules, our observation suggests
that CRMP2-induced bundling is independent of tubulin
assembly. Importantly, FER-induced phosphorylation of
CRMP2 signiﬁcantly reduced its ability to bundle microtubules
(Fig. 1a). Taken together, our data show that FER has a profound
negative impact on the ability of CRMP2 to induce microtubule
polymerization, elongation, and bundling.
To identify FER phosphorylation sites on CRMP2,
we performed phosphopeptide mapping using liquid chromato-
graphy mass spectrometry (LC-MS) on recombinant CRMP2
with or without prior incubation with FER and identiﬁed six
phosphorylation sites: Y32, Y251, Y275, Y431, Y479, and Y499
(Supplementary Fig. 2a). Using recombinant full-length CRMP2
protein (residues 1–572) and its truncated versions, residues
13–490, 13–516, 13–526, 13–536, 13–546, and 13–556, we found
that the carboxy terminus of CRMP2 is important for its
microtubule bundling activity (Supplementary Fig. 2b, c). We
therefore focused our further analysis on Y479 and Y499
phosphorylation sites. Phosphotyrosine-speciﬁc antibodies for
both sites were raised and these conﬁrmed that FER phosphory-
lated CRMP2 at Y479 and Y499 in vitro (Fig. 2a, b). Importantly,
FER was unable to phosphorylate the Y479F or the Y499F
mutants of CRMP2, indicating the speciﬁcity of the antibodies
in vitro (Fig. 2a, b). The validity of the phosphorylation events
was further conﬁrmed in vitro by showing that the phosphoryla-
tion signal was depleted in a dose-dependent manner following
treatment using a FER/FES inhibitor22 (Supplementary Fig. 3a).
Further analysis revealed that FER phosphorylated CRMP2 in
ovarian cancer cells since FER inhibition or depletion decreased
total CRMP2 tyrosine phosphorylation in the ovarian cancer cell
lines OVCA432 or SKOV3 (Supplementary Fig. 3b, c). In
addition, using immunoprecipitation of endogenous CRMP2
followed by immunoblotting using phospho-antibodies, we
conﬁrmed that Y479 and Y499 were both phosphorylated in
multiple ovarian cancer cell lines (Fig. 2c, d). Importantly,
the depletion of FER (Fig. 2e) or its inhibition (Supplementary
Fig. 3d) in ovarian cancer cells reduced the level of pCRMP2-
Y479. Moreover, FER expression level strongly correlated
(r2 = 0.924) with pY479-CRMP2 level in multiple ovarian cancer
cell lines (Supplementary Fig. 3e, f). Taken together, our data
conﬁrmed that FER phosphorylated CRMP2 at Y479 in ovarian
cancer cells.
A previous report showed that YES kinase phosphorylated
CRMP2 at Y47923. YES was expressed in several ovarian cancer
cell lines but hardly detected in OVCA432 (Supplementary
Fig. 3g). To test the effect of loss of YES on pY479-CRMP2, we
chose OVCAR3 cell line that had high expression of YES kinase
and also expressed FER. The level of pY479-CRMP2 reduced in
OVCAR3 cells with the depletion of either YES or FER kinases,
compared with control non-targeting short interfering RNA
(siRNA) treatment (Supplementary Fig. 3h, i). However, the
depletion of both kinases together did not further reduce pY479-
CRMP2 (Supplementary Fig. 3h, i). This suggests that both
kinases might be in the same pathway.
To understand the potential functional relevance of the
identiﬁed phosphorylation sites, we generated phosphomimetic
mutants of CRMP2 by mutating the tyrosine residues to glutamic
acid (E): CRMP2-Y479E and CRMP2-Y479E/Y499E. These
mutants signiﬁcantly reduced the microtubule bundling activity
of CRMP2 as compared to CRMP2-WT (Fig. 2f). To conﬁrm that
direct phosphorylation of only Y479 and Y499 can impair the
microtubule bundling activity of CRMP2, we generated a CRMP2
mutant in which all the other FER tyrosine phosphorylation sites
were converted to the non-phosphorylatable residue phenylala-
nine (F): CRMP2-Y32F/Y251F/Y275F/Y431F and termed it
CRMP2-4F. This mutant retained the full bundling activity of
the WT CRMP2 (Fig. 2g). We also conﬁrmed that the mutation
from Y to F does not affect the secondary structures of the various
non-phosphorylatable mutants by performing circular dichroism
(CD) spectrophotometry on CRMP2–6F (all six FER phosphor-
ylation sites mutated) and CRMP2 wild type (Supplementary
Fig. 3j). However, phosphorylation of CRMP2-4F by FER
signiﬁcantly reduced the bundling activity of CRMP2 (Fig. 2g).
Thus, the phosphomimetic mutants of CRMP2 or the direct
phosphorylation of Y479 and Y499 signiﬁcantly impair the
microtubule bundling activity of CRMP2.
Since FES kinase, the only other family member of FER kinase,
is known to phosphorylate CRMP2 Y3221, we tested the
signiﬁcance of this phosphorylation on bundling. We generated
Y32 phosphomimetic mutant proteins, including CRMP2-Y32E
and CRMP2-Y32E-Y479E-Y499E. CRMP2-Y32E proteins had no
reduced activity on bundling microtubules, compared with
CRMP2 wild-type protein (Supplementary Fig. 4a). This was
further conﬁrmed by showing that CRMP2-Y32E-Y479E-Y499E
and CRMP2-Y479E-Y499E proteins shared similar activity on
bundling microtubules (Supplementary Fig. 4b).
Structural evidence for disruption of inter-molecular interac-
tions upon phosphorylation of CRMP2. To understand why
phosphorylation of CRMP2 affects its microtubule binding and
bundling ability, we solved its crystal structure, and that of its
phosphomimetic mutant of the FER phosphorylation sites (Y479
and Y499). Our wild-type CRMP2 structure (PDB ID 5MKV) is
also a homo-tetramer as previously reported (residues 13–490;
PDB ID 2GSE and 5LXX)24,25. Speciﬁcally, it is a dimer of
dimers25 (Fig. 3a), and the large buried surface (12,690 A2) sug-
gests that the tetrameric state is biologically relevant. Our struc-
ture suggests that the phosphorylation of Y479 would disrupt the
CRMP2 tetramer and that of Y499 would impair microtubule
binding. Even though neither Y479 nor Y499 are located near the
dimerization interface (Fig. 3a, left panel), a close investigation of
Fig. 2 FER phosphorylates CRMP2 at Y479 and Y499. a, b Recombinant GST-CRMP2 (residues 1–516), GST-CRMP2-Y479F (residues 1–516), or GST-
CRMP2-Y499F (residues 1–516) were puriﬁed and used for in vitro kinase assays in the absence or presence of active GST-tagged truncated FER protein
(residues 521–822). The samples were analyzed by SDS-PAGE, and immunoblotted using the indicated antibodies. IB immunoblot. c, d Lysates of the
indicated ovarian cancer cell lines were immunoprecipitated using an anti-CRMP2 antibody. The samples were analyzed by SDS-PAGE, and immunoblotted
with the indicated antibodies. CRMP2 was loaded as a control for protein input. e Lysates of the ovarian cancer cell line OVCA432, which was treated with
non-targeting (nt) siRNA or FER siRNA, were immunoprecipitated with anti-CRMP2 antibody. The samples were analyzed by SDS-PAGE, and
immunoblotted with the indicated antibodies. f, g The indicated recombinant CRMP2 wild-type or mutant proteins were puriﬁed and incubated with
paclitaxel-stabilized rhodamine-labeled microtubules for 40min at room temperature. Bar plots represent the mean + s.e.m. of microtubule width from at
least 150 individual microtubules per condition tested. Shown are typical results from at least three independent replicates. Scale bar is 10 µm
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the tetramerization interface (Fig. 3a, right panel) shows that
Y479 is positioned at the carboxy-terminal helix of each chain
which is crucial for the dimers to associate and form tetramers.
Tetramers are formed by the interaction of the carboxy-terminal
helix from each dimer with residues 372–379 of the neighboring
chain from the second dimer (Fig. 3a, right panel, zoom-in).
Judging by the local environment around Y479, which is buried
in a fairly hydrophobic cavity (Supplementary Fig. 5a), we esti-
mate that if phosphorylated, it would cause a major change in the
tetrameric state of the protein24 and its microtubule bundling
activity. Our wild-type CRMP2 protein construct has 26 extra
residues (residues 491–516) at the carboxy terminus as compared
to the constructs of the previously solved structures (PDB ID
2GSE and 5LXX). However, in the crystal structure, the electron
density is only best visible up to residue 507, in 1 out of the 4
chains, suggesting ﬂexibility in this region. The residues starting
from 490 onwards seem to be interacting with their dimer partner
either via hydrogen bonds or salt bridges (Fig. 3a, left panel). This
interaction was not seen in previous structures because the con-
structs were too short. We speculate that the ﬂexible carboxy
terminus is required for the CRMP2 to probe and associate with
the microtubules. The fact that Y499 is located in this region
(Fig. 3a, left panel) and that our previous experiments with the
carboxy-terminal truncation mutants showed this region to be
important for bundling microtubules, we hypothesized that if
Y499 is phosphorylated, the carboxy terminus will not be able to
bind the microtubules efﬁciently.
To test our hypotheses, we crystallized the phosphomimetic
mutant of CRMP2 where the two tyrosine residues (Y479 and
Y499) were mutated to glutamic acid (E). The structure (PDB ID
5MLE) conﬁrmed that the mutant was a dimer instead of a
tetramer (Fig. 3b). Comparison with wild-type CRMP2 showed
that the phosphomimetic Y479E introduces a charge in a
hydrophobic cavity that disrupts the tetramerization interface
(Fig. 3c). Analytical gel ﬁltration further validated that phospho-
mimetic mutant is a dimer in solution as compared to the
tetrameric wild-type CRMP2 (Supplementary Fig. 5b).
We next tested the functional consequences of Y479
phosphorylation in the ovarian cancer cell line OVCA432
using ectopic expression of the wild-type CRMP2, CRMP2-
Y479E phosphomimetic mutant, or CRMP2-Y479F phosphor-
ylation-resistant mutant. As expected, the wild-type CRMP2
or its phosphorylation-resistant mutant co-localized with
the metaphase spindle microtubules (Fig. 4a and Supplemen-
tary Fig. 6a). However, CRMP2-Y479E showed poor or no
co-localization with metaphase spindle microtubules (Fig. 4a
and Supplementary Fig. 6a). These results were consistent
with our in vitro biochemical and structural data mentioned
above. Taken together, our data suggest that the phosphorylation
of CRMP2 at Y479 and/or Y499 impairs the microtubule
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Fig. 3 Phosphorylation of CRMP2 at Y479 induces oligomerization changes in CRMP2 structure. a (Left panel) Surface representation of a tetramer of
CRMP2 (residues 13–516) showing the dimerization interface. Visible carboxy-terminal (C’) extensions of each chain are shown as ribbons. Reader-visible
Y499 are labeled and shown in cyan. a (Right panel) Tetramerization interface between the dimers is shown. The position of Y479 at the interface is also
highlighted in blue. Zoom-in shows the details of this interface comprising the carboxy-terminal helix of chain A and residues 372–379 of the neighboring
chain B. b Crystal structure of the phosphomimetic mutant CRMP2–2E. (Left panel) Position of E479 is highlighted. (Right panel) Position of SUMOylation
site, K374, is highlighted. c Superposition of CRMP2 wild-type tetramer structure and CRMP2–2E phosphomimetic mutant dimer structure. Zoom-in
showing key differences at the tetramerization interface: chain A (green) of CRMP2 (residues 13–516) has the Y479 (blue) at the carboxy-terminal helix
which interacts with the loop (gray) of chain B (orange). CRMP2–2E mutant (red) has E479 in the position. The mutation introduces a charge in the
hydrophobic cavity, causing the carboxy-terminal helix to unwind and the tetramer to break
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bundling activity of CRMP2 because of impaired binding to
microtubules.
FER phosphorylation of CRMP2 inhibits its microtubule-
stabilizing function in cells. It is well known that microtubule
bundling contributes to microtubule stability in cells. We there-
fore sought to determine the effect of CRMP2 phosphorylation on
its microtubule-stabilizing activity in SKOV3 cells using cold-
resistance assays. Ectopic expression of wild-type
CRMP2 signiﬁcantly increased resistance of microtubules to
cold treatment compared to the empty vector control (Fig. 4b and
Supplementary Fig. 6b), and this was consistent with our in vitro
biochemical data (Fig. 1a). Moreover, ectopic expression of the
phosphorylation-resistant double mutant CRMP2-Y479F/Y499F
resulted in a further signiﬁcant increase in resistance of micro-
tubules to cold treatment compared to wild-type ectopic expres-
sion (Fig. 4b and Supplementary Fig. 6b). Taken together, our
data demonstrate that CRMP2 Y479 and Y499 play critical roles
in regulating the microtubule stabilization activity of CRMP2 in
ovarian cancer cells.
FER regulates microtubule stability via CRMP2 in ovarian
cancer cells. Given the strong biochemical evidence of how FER
phosphorylation of CRMP2 regulates its microtubule-stabilizing
function, we hypothesized that interfering with the function of
FER may confer a therapeutic advantage by sensitizing cells to
paclitaxel via the inhibition of CRMP2 phosphorylation. This was
supported by the observation that FER was ubiquitously expres-
sed in ovarian cancer cell lines (Fig. 5a, b) and strongly expressed
in more than a third of 130 high-grade serous ovarian cancers
(HGSOCs) (Supplementary Fig. 7a, b). In contrast, FES, the only
other family member of FER, was undetectable at mRNA level in
ovarian cancer cell lines (Supplementary Fig. 7c).
We ﬁrst tested the effect of interfering with FER on
microtubule length and stability. For the former, we utilized
scratch assays to polarize microtubules perpendicular to the
direction of the scratch as we previously described in SKOV3
cells26, and measured the length of microtubules from the nuclear
border to the leading edge of the cell. Inactivation of FER using
the inhibitors TAE684 or WZ-4-49-822 in two independent
ovarian cancer cell lines (SKOV3 and OVCA432) induced a
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signiﬁcant increase in microtubule length in a dose-dependent
manner (Supplementary Fig. 7d). To further conﬁrm this
observation, we repeated the experiments using siRNAs depleting
FER in SKOV3 and OVCA432 cancer cell lines. Similarly,
depletion of FER increased microtubule length in both cancer cell
lines (Supplementary Fig. 7e).
We also measured microtubule stability using an anti-
detyrosinated tubulin (Glu-tubulin) antibody as we previously
described12,27. Depletion of FER or its inhibition (using the
TAE684 inhibitor) signiﬁcantly increased microtubule stability in
the SKOV3 ovarian cancer cell line in the presence or absence of
low doses of paclitaxel treatment (Fig. 5c, d). Importantly, this
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was achieved at low doses of the TAE684. This was further
conﬁrmed using a second FER inhibitor WZ-4-49-8 (Supple-
mentary Fig. 7f). Importantly, depletion of CRMP2 rescued the
increase in paclitaxel-induced microtubule stabilization following
FER depletion (Fig. 5e). This result suggests that CRMP2 is
required for enhancing microtubule stability following FER
depletion. Additionally, CRMP2 was ubiquitously expressed in
ovarian cancer cell lines (Supplementary Fig. 7g). It is interesting
that both CRMP1 and CRMP4 were expressed at mRNA level in
several ovarian cancer cell lines (Supplementary Fig. 7h).
Furthermore, immunohistochemistry staining of more than130
HGSOCs showed that CRMP2 was strongly expressed in more
than one third of ovarian cancers (Supplementary Fig. 7i, j). Since
we found that FER and CRMP2 are involved in regulating
microtubule stability, we tested whether FER regulates cell cycle
progression. However, depletion of FER in SKOV3 cells had no
effect on the cell cycle (Supplementary Fig. 7k).
Down-regulation of FER sensitizes ovarian cancer cells to
paclitaxel in culture and in vivo. Since interfering with FER
signiﬁcantly increased microtubule stability (Fig. 5c, d) and since
FER expression level correlates with paclitaxel half-maximal
inhibitory concentration values in ovarian cancer cell lines
(Supplementary Fig. 8a), we hypothesized that loss of FER may
increase paclitaxel cytotoxicity in ovarian cancer cells. Depletion
of FER using siRNAs signiﬁcantly reduced cell proliferation
following paclitaxel treatment in multiple cell lines (Supplemen-
tary Fig. 8b–d). Furthermore, FER inhibition using TAE684,
WZ-4-49-8, or TL-2-59 (compound 8)28 in multiple cell lines
(OC 316, SKOV3, OVCA432, A2780, and Hey) induced sig-
niﬁcant paclitaxel sensitization at a sub-stoichiometric paclitaxel
concentration of 3 nM (Supplementary Fig. 8e–m). Critically, this
sensitization was achieved at sub-lethal doses of the inhibitors
that did not elicit a signiﬁcant reduction in cell proliferation.
Taken together, our data indicate that FER kinase is a potential
therapeutic target for enhancing paclitaxel efﬁcacy in ovarian
cancer.
We next tested whether the down-regulation of FER might
improve the therapeutic effect of paclitaxel in vivo. To test the
combined effect of FER depletion and paclitaxel treatment, we
employed two xenograft models of ovarian cancer (OVCA432
and SKOV3ip1 ovarian cancer cells) and performed in vivo FER
depletion using the well-characterized neutral 1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine (DOPC) nano-liposomal system
for delivery of siRNA as we previously described26 (Fig. 6a). No
signiﬁcant difference was observed in the mouse body weight
between the group of mice treated with paclitaxel alone and the
group of mice treated with both FER siRNA and paclitaxel, in
both of the two xenograft models of ovarian cancer (Supplemen-
tary Fig. 8n). However, in vivo depletion of FER (Supplementary
Fig. 8o) induced a signiﬁcant reduction in the number of tumor
nodules and in tumor weight when combined with paclitaxel
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treatment in comparison with paclitaxel treatment alone
(Fig. 6b–d). Taken together, our data strongly suggest that the
combination of FER depletion and paclitaxel treatment is an
attractive therapeutic strategy in vivo to enhance paclitaxel
response in ovarian cancer.
Discussion
CRMP2 is one of the key modulators of microtubule dynamics but
little is known about the signaling pathways that regulate its
interaction with microtubules. In this work, we show how FER
phosphorylates CRMP2 at Y479 and Y499 to regulate
CRMP2 structure and its interaction with microtubules, respec-
tively. We show that loss of CRMP2 phosphorylation, either via
FER depletion or inhibition, signiﬁcantly sensitizes ovarian cancer
cells to paclitaxel treatment. Our data provide strong evidence that
targeting FER is a plausible therapeutic strategy to enhance the
efﬁcacy of paclitaxel in treating ovarian and potentially other
cancers. This is important because in spite of their wide use, taxanes
only elicit a response in less than 50% of patients who receive it.
CRMP2 has previously been shown to associate with micro-
tubules in cells, and to bind to tubulin heterodimers to promote
microtubule assembly13. CRMP2 has been reported to be phos-
phorylated by GSK3β, CDK5, and Rho kinase at a number of
serine and threonine residues at the carboxy terminus. These
modiﬁcations impair the ability of CRMP2 to bind to tubu-
lin16,18,19. FES, the only family member of FER, has previously
been shown to phosphorylate CRMP2 at Y3221,29. However, our
data demonstrate that phosphorylation mimicking at Y32 does
not impair the microtubule bundling activity of CRMP2 (Sup-
plementary Fig. 4). Our study reveals that FER, which was
recently found to promote ovarian cancer metastasis20, phos-
phorylates CRMP2 at two sites, Y479 and Y499. Both of these
sites are important in regulating microtubule stability in vitro and
in cells. A limitation of this study is that the anti-pY479-CRMP2
antibody was not suitable for immunohistochemistry. Therefore,
it was not possible to test the correlation between the level of FER
and pY479-CRMP2 in patient samples. It is, therefore, not pos-
sible to test whether or not the intrinsic FER activity can correlate
with paclitaxel resistance in ovarian cancer patients.
CRMP2 is critical for axon formation by promoting micro-
tubule assembly13. However, GSK3β and Rho kinase phosphor-
ylate CRMP2 at T514 and S555, and inactivate it by impairing its
association with tubulin dimers18,19 and inhibiting microtubule
assembly. Our study reveals that FER phosphorylated CRMP2 at
Y479 and Y499, reducing its microtubule bundling activity
(Fig. 2). Though all these three kinases have negative impact on
the microtubule assembly activity of CRMP2, FER kinase reg-
ulates microtubule assembly via a different mechanism, compared
with GSK3β and Rho kinase that are both known to be expressed
in ovarian cancer cells30,31. Our study shows that phosphoryla-
tion at Y479 induces CRMP2 conformation change, impairing its
tetramerization (Fig. 3), which is critical for its microtubule
bundling function. However, how this conformation defect
impairs CRMP2 activity should be investigated by resolving the
structure of CRMP2 microtubule complex, using techniques such
as cryo-electron microscopy (cryo-EM).
A previous report suggested that the YES kinase phosphor-
ylates CRMP2 at Y479 and regulates T lymphocyte migration23.
However, the biochemical and functional effect of such phos-
phorylation was not identiﬁed. Additionally, to our knowledge,
this is the ﬁrst report to show that FER phosphorylates Y499 of
CRMP2. These two phosphorylation sites (Y479 and Y499) might
act as biomarkers for detecting on-target activity of FER inhibi-
tors in a therapeutic context, providing important translational
signiﬁcance. In the future, it will be interesting to investigate
whether FER and YES co-regulate microtubule stability in ovarian
cancers in terms of modulating CRMP2 activity on microtubules
as YES is expressed in some ovarian cancer cell lines and also
involved in the phosphorylation at Y479 of CRMP2 in the ovarian
cancer cell line (Supplementary Fig. 3g–i). It will also be of
interest to test whether targeting YES kinase can enhance pacli-
taxel response. It is important to note that CRMP1 and CRMP4
also are expressed in ovarian cancer cells (Supplementary
Fig. 7h). Thus, it is possible that FER might also phosphorylate
CRMP1 or CRMP4 at Y479 and Y499 in ovarian cancer cells
since these two sites are highly conserved.
To understand the structural mechanism by which FER
phosphorylation of CRMP2 affects its microtubule interaction, we
solved structures of CRMP2 (wild-type and phosphomimetic
mutant) (Fig. 3 and Supplementary Fig. 10). The new structural
information has enabled us to speculate that both the intact tet-
ramer conformation and the carboxy terminus of CRMP2 are
pivotal for CRMP2 function to bundle microtubules.
Our data indicate that CRMP2 needs to be a tetramer to bundle
microtubules effectively. Our wild-type structure depicts CRMP2
as a tetramer and accordingly, in in vitro microtubule bundling
assay with CRMP2, the microtubules are seen as thick bundles. The
non-mutated structure also shows that Y479 is at the tetra-
merization interface between two dimers. Once this interface is
broken by phosphorylation of Y479, the tetramer would fall apart,
as indicated by the structure of phosphomimetic mutant. This
would cause a signiﬁcant decline in microtubule bundling, which is
what we observe in our in vitro microtubule bundling assay
(Fig. 2f, g). Future work using cryo-EM will be important in
visualizing the two modes of interaction. Our work reports the
existence of CRMP2 as a dimer upon phosphorylation which, to
our knowledge, has not been observed before. This is especially
interesting, considering the recent study reporting an interplay
between phosphorylation and SUMOylation regulating the biolo-
gical functions of CRMP232. The investigators show the existence
of structurally conserved SUMOylation site, K374, which remains
buried at the tetrameric interface of CRMP2. They further pre-
dicted that this site would be solvent accessible if interface was
disrupted. Our phosphomimetic mutant structure, indeed, is in
accordance with this prediction and clearly shows that K374 is
solvent exposed and available for SUMOylation in the dimeric
form (Fig. 3b, right panel).
Moreover, Y499 is located in the carboxy-terminal region of
CRMP2. The carboxy terminus might be critical for binding
microtubules, as shown in this and previous studies14. The
importance of the carboxy-terminal region is further highlighted by
the presence of post-translational modiﬁcations that are thought to
be critical for regulating tubulin function16,18,19. These observations,
along with the crystal structures that show poor electron density at
the carboxy terminus, allow us to speculate that the carboxy-
terminal region acts as a ﬂexible anchor for interacting with
microtubules and that phosphorylation reduces its ability to do so.
In summary, our work provides important insights into
CRMP2-mediated bundling of microtubules and its regulation by
FER phosphorylation. Due to the poor pharmacokinetics of
paclitaxel, enhancing its efﬁcacy at sub-stoichiometric con-
centrations is clinically important. We provide strong evidence
that targeting FER may augment the therapeutic efﬁcacy of
paclitaxel at sub-stoichiometric concentrations by increasing
microtubule stabilization.
Methods
Tissue culture cells. A2780, Hey, OC 316, and UPN251 cell lines were obtained
from Robert C. Bast lab in MD Anderson Cancer Centre. OVCA432 cell line was
obtained from Anil K. Sood lab in MD Anderson Cancer Centre. OVCAR3,
SKOV3, and HEK-293 cell lines were obtained from ATCC. SKOV3 were grown in
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McCoy’s 5A medium, supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin–streptomycin. The other cell lines were grown in Dulbecco’s modiﬁed
Eagle's medium supplemented with 10% FBS and 1% penicillin–streptomycin. The
cell lines have been tested for mycoplasma contamination.
Validated non-targeting siRNA (UGGUUUACAUGUCGACUAA), two FER
siRNAs (GGAGUGACCUGAAGAAUUC and GGAAAGUACUGUCCAAAUG),
and CRMP2 siRNA (GAAGGGAACUGUGGUGUAU) were purchased from
Dharmacon, GE Healthcare. OVCA432 and SKOV3 cells were transfected with 40
nM siRNA using Lipofectamine RNAiMax (Thermo Fisher Scientiﬁc) according to
the manufacturer’s instructions.
For transient transfections, plasmid DNA and FuGENE HD reagent (Promega)
were diluted in Opti-MEM medium in a 1:3 ratio at 3.0 µg DNA per well, and
incubated for 15 min at room temperature before being added to plated cells.
OVCA432 cells were used for lentiviral transduction. Lentiviral vectors were
packaged and infected as following description. In brief, the envelop plasmid
pMD2.G (a gift from Dr. Didier Trono; Addgene, 12259), packaging
plasmid psPAX2 (a gift from Dr. Didier Trono; Addgene, 12260), and pLX302 (a
gift from Dr David Root33) based vectors were cotransfected into HEK-293, and
viruses were harvested 48 h after transfection. Then, OVCA432 cells were
transduced with lentiviral particles carrying plasmids containing the gene of
interest. Primers used for lentiviral constructs are listed in Supplementary Table 1.
Puromycin (0.5 mg/ml) selected colonies were screened for further analysis.
Cloning and site-directed mutagenesis. CRMP2 complementary DNA (cDNA)
was obtained from OriGene. Recombinant CRMP2 DNA was sub-cloned into
individual vector after DNA sequence veriﬁcation. Recombinant DNA was
ampliﬁed by speciﬁc primers listed in Supplementary Table 1.
Reverse and real-time qPCR. Total RNA was isolated from cell lines using
RNeasy mini Kit (Qiagen) and cDNA was synthesized using TaqMan Reverse
Transcription kit (Applied Biosystems). Quantitative (real-time) PCR (qPCR) was
conducted in a 20 µl reaction volume using the SYBR Green PCR Master Mix
(Applied Biosystems) according to the manufacturer’s introductions. The samples
were analyzed on an ABI Prism 7000 sequence detection system (Applied Bio-
system, Foster City, USA). The primer sequences for qPCR are provided in Sup-
plementary Table 2.
Recombinant protein production. Protein expression constructs were trans-
formed into Escherichia coli Tuner (DE3) strains to generate the recombinant
proteins, which were induced by 0.5 mM isopropyl β-D-thiogalactopyranoside and
incubated at 16 °C overnight. Bacterial cells were harvested at 4000×g and lysed by
sonication in the presence of the buffer containing 500 mM NaCl, 10% glycerol, 50
mM HEPES, pH 7.5, and 0.5 mM Tris(2-carboxyethyl)phosphine hydro-
chloride (TCEP). Further puriﬁcation of these proteins was performed with nickel-
nitriloacetic acid resin (Novagen) according to the manufacturer’s instructions.
Proteins were dialyzed against a buffer containing 300 mM NaCl, 10% glycerol, 20
mM HEPES, pH 7.5, and 0.5 mM TCEP. Further puriﬁcation of the proteins was
done by size exclusion gel ﬁltration in 300 mM NaCl, 10% glycerol, 20 mM HEPES,
pH 7.5, and 0.5 mM TCEP. The proteins were concentrated and snap frozen in
liquid nitrogen before storage at −80 °C.
In vitro kinase assay. Commercial FER proteins were obtained from Thermo
Fisher Scientiﬁc. Then, 12 µM CRMP2 wild-type or CRMP2 mutant proteins and 3
µM FER protein were incubated with 80 µM ATP (SignalChem) in kinase assay
buffer 1 (SignalChem, 25 mM MOPS, pH 7.2, 25 mM MgCl2, 5 mM EGTA, 2 mM
EDTA, 0.25 mM dithiothreitol (DTT), 12.5 mM β-glycerol-phosphate) in a 25 µl
reaction. Reactions were incubated at 30 °C for 20 min before adding 2× NuPAGE
LDS sample buffer (Thermo Fisher Scientiﬁc) and boiling at 95 °C for 5 min.
Mass spectroscopy. LC-MS/MS experiments were performed using a Dionex
Ultimate 3000 RSLC nanoUPLC (Thermo Fisher Scientiﬁc Inc., Waltham, MA,
USA) system and a QExactive Orbitrap mass spectrometer (Thermo Fisher Sci-
entiﬁc Inc.). Separation of peptides was performed by reverse-phase chromato-
graphy at a ﬂow rate of 300 nl/min and a Thermo Scientiﬁc reverse-phase nano
Easay-spray column (Thermo Scientiﬁc PepMap C18, 2 µm particle size, 100 A
pore size, 75 µm i.d. x 50 cm length). Peptides were loaded onto a pre-column
(Thermo Scientifc Pepmap 100 C18, 5 µm particle size, 100 A pore size, 300 µm i.d.
x 5 mm length). The LC eluent was sprayed into the mass spectrometer by means
of an Easy-spray source (Thermo Fisher Scientiﬁc Inc.). All m/z values of eluting
ions were measured in an Orbitrap mass analyzer, set at a resolution of 70,000.
Data-dependent scans (Top 20) were employed to automatically isolate and gen-
erate fragment ions by higher energy collisional dissociation in the quadrupole
mass analyser and measurement of the resulting fragment ions was performed in
the Orbitrap analyser, set at a resolution of 17,500. Peptide ions with charge states
of between 2+ and 5+ were selected for fragmentation. Data were processed using
Protein Discoverer (version 1.4., Thermo Fisher). Brieﬂy, all data were converted to
mgf ﬁles and submitted to the Mascot search algorithm (Matrix Science, London,
UK) and searched against a custom database containing only the CRMP2 sequence
using a modiﬁcation of tyrosine phosphorylation (Y). Peptide identiﬁcations were
accepted if they could be established at greater than 95% probability.
Western blotting. Samples were separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) using NuPage Bis-tris
polyacrylamide gels (Thermo Fisher Scientiﬁc) and transferred to nitrocellulose
membrane using the iBlot dry gel transfer system (Invitrogen). Membranes were
incubated with primary antibodies overnight at 4 °C before washing with Tris-
buffered saline and 0.1% Tween-20. Secondary antibodies (anti-rabbit horseradish
peroxidase (HRP) conjugated and anti-mouse HRP conjugated, Abcam) were
incubated with membranes for 1 h at room temperature. Rabbit anti-CRMP2-
pY479 and rabbit anti-CRMP2-pY499 antibodies were generated by Biogene, using
peptides (CFPDFV-pY-KRIKA, for pY479) and (CVPRGL-pY-DGPV, for pY499)
to immunizing rabbits. They were used in 1:1000 dilutions for western blot. The
information and used dilutions of commercial primary antibodies used in this
paper is provided in Supplementary Table 3. The original western blots are pro-
vided in Supplementary Fig. 9.
Immunoprecipitation. Cells were seeded into 10 cm culture dishes before lysis in
lysis buffer (50 mM HEPES, pH 7.0, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF,
10 mM sodium pyrophosphate, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1
mM Na3VO4, 10 µg/µl Aprotinin, 10 µg/ml Leupeptin, and 1 mM phe-
nylmethylsulfonyl ﬂuoride). Lysates were pre-cleared with 40 µl protein G
sepharose slurry for 30 min. Then, 2 mg cell lysate was incubated with 3 µg anti-
body overnight at 4 °C, followed by 60 µl protein G sepharose slurry incubation for
4 h at 4 °C. Samples were washed comprehensively with lysis buffer ﬁve times prior
to addition of 20 µl 4× NuPAGE sample buffer (Thermo Fisher Scientiﬁc). Western
blots were performed as described previously.
Immunoﬂuorescence and confocal microscopy. Cells were grown on glass cov-
erslips prior to ﬁxation with 4% paraformaldehyde for 3 min at room temperature
and subsequent permeabilization with ice-cold 100% ethanol overnight at −20 °C.
Cells were then washed three times with wash buffer (Tris-buffered saline, 0.2%
Triton X-100 (Sigma) and 0.04% SDS (Sigma)). Cells were further incubated with
blocking buffer (Tris-buffered saline, 0.2% Triton X-100 (Sigma), 0.04% SDS
(Sigma) and 1.5% bovine serum albumin (Sigma)) for 30 min and incubated with
primary antibodies for 1 h at room temperature. Cells were incubated with ﬂuor-
escent secondary antibodies (Alexa ﬂuor-488 or Alexa ﬂuor-568, Invitrogen) for 1 h
at room temperature in the dark. Images were captured using the Zeiss microscopy
with a 63 ×oil objective.
Microtubule polymerization and bundling visualization. Tubulin was prepared
from pig brains according to the previous report34. Then, 30 µM tubulin in PEM
buffer (80 mM PIPES-KOH, pH 6.9, 1 mM EGTA, and 1 mM MgCl2) were used to
investigate microtubule polymerization in the absence or presence of CRMP2 or
pCRMP2 proteins at the indicated concentration. Microtubule polymerization was
analyzed by measuring the absorbance at 350 nm at 37 °C. This assay was per-
formed using a SpectraMax M2e microplate reader (Molecular Devices).
Rhodamine-tubulin was labeled with 5-Carboxy-tetramethylrhodamine N-
succinimidyl ester (Sigma-Aldrich), according to the previous report35. Rhodamine
microtubules were incubated with PEM buffer (80 mM PIPES-KOH, pH 6.9, 1 mM
EGTA, and 1 mM MgCl2) in the presence of 10 µM paclitaxel in a 37 °C water bath
for 40 min. Rhodamine-labeled microtubules were incubated with recombinant
CRMP2 at the ratio of 4:1 for 30 min at room temperature. Then, 2 µl of each
reaction was mounted on a poly-lysine-coated coverslip and samples were observed
with the Zeiss microscopy using a 100× oil immersion objective. For microtubule
bundle width calculation, we measured the maximum width of each microtubule,
using Image J software. More than 150 microtubules (more than 8 µm of length)
were randomly selected to be measured.
Microtubule bundling was also observed via negative stain electron microscopy.
A total of 10 µl pre-assembled microtubules in the absence or presence of CRMP2
were incubated with fresh glow discharge carbon 300 mesh copper grids (TAAB
laboratories) for 2 min. Grids were then blotted with ﬁlter paper before being
stained with 2% uranyl acetate for 10 s. Grids were imaged on a FEI Tecnai 12 TEM
equipped with a Gatan US1000 CCD camera at 120 kV before being air dried.
Microtubule elongation visualization by TIRFM. Flow cells were prepared as
previously described36. Flow cells were incubated with 1 µg/ml anti-α-tubulin
antibody (Sigma-Aldrich) for 5 min, followed by washing with PEM buffer and 1%
Pluronic F127 (Sigma-Aldrich). Next, 400 nM rhodamine-GMPCPP (Guanosine-
5′-[(α,β)-methyleno]triphosphate) microtubules (10% rhodamine labeled) were
injected into ﬂow cell after it was washed with PEM buffer again. GMPCPP (Jena
Bioscience)-labeled microtubules were prepared as previously described37. After 5
min, the ﬂow cell was washed with 1 volume of PEM buffer, and then was injected
with 7.5 µM rhodamine-tubulin (50% labeled) in the presence of 400 nM CRMP2
or pCRMP2. The reaction was conducted in the following buffer: 80 mM PIPES-
KOH, pH 6.9, 1 mM EGTA, 1 mM MgCl2, 50 mM NaCl, 50 mM DTT, 1 mM GTP,
15 mM glucose, 20 mg/ml catalase, 100 mg/ml Glucose oxidase, and 0.5%
methylcellulose. Single microtubule ﬁlaments were observed immediately by TIRF
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illumination with an Olympus IX83 microscopy equipped with a 150× oil objective
(1.45 numerical aperture). Images were collected for 5 min with an interval of 5 s
using a Photometrics Evolve Delta EMCCD camera (Photometrics) with Olympus
cellSens software. For microtubule elongation rate calculation, we measured the
length of a single microtubule at starting point (T1, second), which gave the length
(L1, µm). Then, we selected the ending point (T2, second), and measured the
length of the same single microtubule (L2, µm). The length of microtubules was
measured using Image J software. More than 25 microtubules were randomly
selected to be measured. Microtubule elongation rate was calculated using the
following equation: (L2−L1)/[(T2−T1)×60].
Colony formation assay. A2780, Hey, OC316, OVCA432, and SKOV3 cells were
seeded into 6-well plates at 500 cells/well. After 48 h, cells were treated with
indicated concentrations of FER inhibitors (TAE684, WZ-4-49-8, or TL-2-59) or
dimethyl sulfoxide (DMSO) vehicle control as indicated in the ﬁgure legend (Sup-
plementary Fig. 8e–m). After 48 h of inhibitor treatment, cells were treated with or
without 3 nM paclitaxel in the presence of FER inhibitors. After 6 days, plates were
ﬁxed with 50% methanol and stained with Coomassie Brilliant Blue (Sigma-
Aldrich).
Cell cycle analysis. Analysis of SKOV3 cell cycle was performed using ﬂow
cytometry and 4',6-diamidino-2-phenylindole (DAPI) staining. SKOV3 cells were
trypsinized and re-suspended in 1.2 ml phosphate-buffered saline (PBS). Then, 3
ml ice-cold 95% ethanol was added dropwise while being vortexed, following by
two washes with PBS. Next, 1 × 106 cells were re-suspended in 1 ml DAPI (D9542)
staining solution, which contains 0.1% Triton X, 1 μg/ml DAPI, and PBS. Cells
were applied to analysis after incubation on ice for 30 min.
Immunohistochemistry. Samples for tissue arrays were collected retrospectively
within a translational study that was ethically approved (Number 11/SC/014,
Berkshire NRES Committee).
To investigate the expression level of FER or CRMP2 in high-grade serous
ovarian cancers, tissue arrays comprising samples from 130 HGSOCs were used.
Tissue sections of 4 μm thickness were cut from the samples. Automated staining
was performed with the Leica BOND-MAX autostainer (Leica, Microsystem) using
the following conditions: (1) antigen retrieval at 100 °C for 20 min with Epitope
Retrieval Solution 1 (AR9961, Leica Biosystems); (2) primary antibody incubation
with the FER antibody (ab130199) at 1:300 dilution or the CRMP2 antibody
(ab129082) at 1:200 dilution for 15 min; (3) then detection using the BOND™
Polymer Reﬁne Detection System (DS9800, Leica Biosystems) as per the
manufacturer’s instructions. Stained slides were scanned at 40× magniﬁcation
using the Aperio slide scanner (Aperio). The ImageScope software (v11.2.0.780,
Aperio) was used for quantiﬁcation of cytoplasmic staining. To score FER or
CRMP2 positivity in the samples, regions of interest (ROIs) were deﬁned, using the
“positive pen tool”. The marked ROIs were analyzed with the algorithm “positive
pixel count v9”. It scored the intensity of staining of all cells within the marked
areas and automatically classiﬁed cells into 4 categories according to the pixel
intensity values: (1) no detectable signal, (2) weak intensity of staining, (3)
moderate intensity of staining, and (4) strong intensity of staining. Sum of (1), (2),
and (3) was deﬁned as low expression, and (4) was deﬁned as high expression. The
percentage of cells with low or high expression of FER or CRMP2 to the total
number of cells scored in a ROI was presented.
In vivo experiments. Nude immunodeﬁcient C57BL/6 mice were obtained from
the National Cancer Institute, Frederick Cancer Research and Development Center
(Frederick, MD, USA), and were bred and maintained according to institutional
guidelines. All animal experiments were performed in accordance with the pro-
tocols approved by the MD Anderson Cancer Center Institutional Animal Care
and Use Committee.
To investigate the combinatorial effects of paclitaxel treatment and FER
depletion on tumor growth, the ovarian cancer cell lines SKOV3ip1 or OVCA432
were injected into the peritoneal cavity of female nude mice at approximately
12 weeks of age. To induce tumor development, SKOV3ip1 or luciferase-labeled
OVCA432 ovarian cancer cells were trypsinized and suspended in 200 μl of Hanks'
balanced salt solution (Gibco, Carlsbad, CA) before being injected into mice
intraperitoneally (SKOV3ip1, 1.0 × 106 cells/mouse; OVCA432, 1.5 × 106 cells/
mouse). After 1 week, four separate groups were treated as follows: (1) control non-
targeting siRNA/DOPC; (2) non-targeting siRNA/DOPC + paclitaxel; (3) FER
siRNA/DOPC; and (4) combination of paclitaxel and FER siRNA/DOPC. Each
treatment was administered intraperitoneally. Each group consisted of 10 mice.
Paclitaxel was introduced 1 day after siRNA incorporation for OVCA432 at a dose
of 35 μg per mouse once a week. At 4 weeks after treatment (or mice in any group
became moribund), all four groups of mice were sacriﬁced and the mouse weight,
tumor weight, and number of tumor nodules were recorded. In addition, tumor
tissue was ﬁxed in formalin for parafﬁn embedding.
siRNA for in vivo delivery was incorporated into DOPC (Avanti Polar Lipids,
Inc.) as described previously38,39. Brieﬂy, 5 µg of siRNA and DOPC were mixed in
the presence of excess tertiary butanol at a ratio of 1:10 (w/w). After addition of
Tween-20 (1:19 Tween-20:siRNA/DOPC), the mixture was frozen in an acetone dry
ice bath and lyophilized. Liposomes were reconstituted with 200 µl (to achieve a 200
µg/kg concentration) PBS and administered into mice intraperitoneally. Mice were
treated for 6 weeks biweekly to have siRNA bioavailability and sustained silencing
effect.
CD spectrophotometry. CD spectra were recorded on a J-815 spectropolarimeter
(JASCO) at 20 °C with a scan speed of 100 nm/min using 0.1 cm path length quartz
cells from Starna Scientiﬁc UK. The concentration of both full-length CRMP2
wild-type and full-length CRMP2–6F was 0.2 mg/ml. Data points were collected
with a resolution of 0.2 nm, an integration time of 1 s, and a slit width of 1 nm.
Each spectrum shown is the result of nine averaged consecutive scans from which
buffer scans were subtracted.
Analytical gel ﬁltration. CRMP2 wild type (residues 13–516) and CRMP2–2E
(residues 13–516) at concentrations of 0.5 mg/ml were run on Sepax SRT SEC-300
column connected to Dionex™ HPLC System in buffer containing 300 mM NaCl,
10% glycerol, 20 mM HEPES, pH 7.5, and 0.5 mM TCEP with injection volume of
65 µl.
Structure determination. CRMP2 (residues 13–516) was crystallized using sitting
drop vapor diffusion method at 20 °C by mixing 100 nl of protein (19 mg/ml) with
50 nl of crystallization solution (0.2 M ammonium acetate, 30% PEG 4000, and 0.1
M citrate buffer, pH 5.5) and equilibrating against 20 µl of crystallization solution.
Crystals were cryo-protected with 25% ethylene glycol mixed in crystallization
buffer. X-ray diffraction dataset was collected to 1.8 Å at 100 K on Diamond
synchrotron beamline I03. The data were processed using XDS and 5% of the
reﬂections were randomly assigned to calculate the free R factors. The structure was
phased using CCP4- Phaser40 by providing CRMP2 tetramer (residues 13–490,
PDB: 2GSE)25 as the template. Single copy of the tetramer was found in the
asymmetric unit. The structure was reﬁned using CCP4-Refmac541. The data
collection and reﬁnement statistics are provided in Supplementary Table 4.
CRMP2 (residues 13–516)-2E phosphomimetic mutant was crystallized using
sitting drop vapor diffusion method at 20 °C by mixing 50 nl of protein (12.91 mg/
ml) with 100 nl of crystallization solution (0.2 M magnesium chloride, 25% PEG
3350, and 0.1 M bis-tris buffer pH 6.5) and equilibrating against 20 µl of
crystallization solution. Crystals were cryo-protected with 25% ethylene glycol
mixed in crystallization buffer. X-ray diffraction dataset was collected to 2.48 Å at
100 K on Diamond synchrotron beamline I04–1. The data were auto-processed
using xia242. The structure was phased using CCP4- Phaser40 by providing a
monomer from CRMP2 tetramer (residues 13–490, PDB: 2GSE)25 as the template.
Two copies of the monomer were found in the asymmetric unit. The structure was
reﬁned using CCP4-Refmac541. The data collection and reﬁnement statistics are
provided in Supplementary Table 4.
Quantiﬁcation and statistical analysis. Levels of signiﬁcance were performed
with Student’s t-test while comparing two groups or with one-way analysis of
variance while comparing more than two groups using GraphPad Prism, and
means+s.e.m. values were presented.
Data availability. The PDB ids for CRMP2 (residues 13–516) and CRMP2–2E
(residues 13–516) structures reported in this paper are: 5MKV and 5MLE,
respectively. All other remaining data are available within the article and Supple-
mentary Files, or available from the authors upon request.
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